How effective is the Chinese Coronavac vaccine?
From Coronavac, a vaccine developed by the Chinese pharmaceutical company Sinovac, low immune response in over 55 according to a study coordinated by the Faculty of Medicine of the University of Sao Paulo in Brazil. But previous research on effectiveness …
The Chinese Coronavac vaccine for people over 55 is not very effective.
The response to Sars Cov-2 virus in people who have taken double doses of the Coronavac vaccine, manufactured by China's Sinovac Biotech Ltd, is less intense in most men over 55.
This is the preliminary result of the study coordinated by the Faculty of Medicine of the University of Sao Paulo in Brazil and not yet subjected to examination by the scientific community, reported by Ansa .
It is therefore recommended to administer a third dose of vaccine for the over eighty year olds and then for the over sixty year olds.
Results that clash with those of a previous study: two doses of the CoronaVac vaccine offer 83.5% protection against symptomatic Covid-19 and 100% protection against hospitalization. This is what emerged from an analysis, the results of which were published in The Lancet in July and presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).
Just last July, the Chinese anti-Covid vaccine received emergency approval from the World Health Organization (WHO). Coronavac has been approved for emergency use in more than 20 countries and has been in Phase 3 trials since mid-2020 in Brazil, Indonesia, Chile and Turkey.
All the details.
THE STUDIO OF THE SAN PAOLO UNIVERSITY OF BRAZIL
Based on blood draws from 70 people who had already had the disease and 100 vaccinated with the double dose of Coronavac, the study indicated that only a third of men over 55 have a strong burden of and that this response is reduces after the age of 80.
THE IMMUNE RESPONSE TO VACCINE DECREASES SINCE 80 YEARS ONWARDS
“The diminished response to the vaccine increases from the age of 80 onwards. This clearly demonstrates that the vaccine regimen used is not sufficient to provide reasonable coverage against serious illness and death, ”notes Jorge Kalil, researcher who led the study.
A THIRD DOSE RECOMMENDED
For this reason, the authors of the research recommend the administration of a third dose of a third dose of vaccine first in people over 80 and then, when possible, in over 60.
WHAT A STUDY PUBLISHED ON LANCET IN JULY SUPPORTED
Yet, according to an analysis whose results were published in the Lancet in July, the vaccine developed by the pharmaceutical company Sinovac is safe and provides 100% protection against hospitalization and 83.5% protection against Covid. 19 symptomatic after two doses.
The large-scale phase 3 study of the inactivated vaccine, conducted in Turkey between September 2020 and January 202, involved more than 10,000 participants aged 18 to 59. Participants were given two doses of CoronaVac 14 days apart.
Most of the adverse effects reported (90%) were mild, including fatigue, injection site pain, and myalgia, which occurred within seven days of injection. No serious effects recorded during the study period.
The analysis of the immune response induced by the vaccine has also shown the development of antibodies in 90% of vaccinated people, but decreasing with increasing age.
WHAT EMERGED FROM A STUDY ON BELL'S PARALYSIS
Finally, according to a study published in the journal The Lancet Infectious Diseases, the risk of Bell's palsy, a type of facial paralysis, is higher after the CoronaVac vaccine, but should not be a deterrent to vaccination.
The Hong Kong study assessed the risk of the adverse event within 42 days of vaccination.
The study involved 28 clinically confirmed cases of Bell's palsy after Sinovac's CoronaVac injection reported among nearly 452,000 individuals who received the first dose of the vaccine and 16 cases after Pfizer / BioNtech's vaccine from more than 537,000 individuals.
"Our findings suggest an overall increased risk of Bell's palsy after CoronaVac vaccination," according to the study.
However, the study argues that "The beneficial and protective effects of the inactivated Covid-19 vaccine far outweigh the risk of this generally self-limiting adverse event."
This is a machine translation from Italian language of a post published on Start Magazine at the URL https://www.startmag.it/sanita/quanto-e-efficace-il-vaccino-cinese-coronavac/ on Wed, 08 Sep 2021 14:31:55 +0000.